Aprogen Pharma: "Warrant Delisting Unrelated to Common Stock"

[Asia Economy Reporter Hyungsoo Park] Aprogen Pharmaceuticals explained that the suspension of trading and delisting of the subscription warrants market due to the expiration of the subscription warrant exercise period is unrelated to the common stocks listed on the KOSPI market.

Aprogen Pharmaceuticals stated that the suspension of trading and delisting of subscription warrants announced by the Korea Exchange KOSPI Market Division on the 10th regarding ‘Suspension of Trading of Subscription Warrants (Aprogen Pharmaceuticals 13WR)’ is not related to the company’s delisting.

The 13th subscription warrant bonds issued on July 20, 2017, will mature on the 20th of next month, leading to the suspension of trading in the subscription warrants market for Aprogen Pharmaceuticals 13WR subscription warrants listed on the subscription warrants market due to the expiration of the exercise period.

A company official explained, "This announcement is unrelated to the currently traded common stocks but may cause misunderstandings such as suspension of trading or delisting of common stocks. It only applies to Aprogen Pharmaceuticals 13WR listed on the subscription warrants market and has no relation to the listing status of common stocks listed on the KOSPI market."

On the 20th of last month, the Korea Exchange KOSPI Market Division announced an investment caution notice regarding ‘Expiration of the Exercise Period and Delisting Notice of Aprogen Pharmaceuticals 13WR Subscription Warrants.’ The relevant subscription warrants will have trading suspended from the 17th and will be delisted on the 21st.

This content was produced with the assistance of AI translation services.